<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597181</url>
  </required_header>
  <id_info>
    <org_study_id>0710-28</org_study_id>
    <nct_id>NCT00597181</nct_id>
  </id_info>
  <brief_title>A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy</brief_title>
  <acronym>Optonol</acronym>
  <official_title>A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optonol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The less invasive nature of the Ex-Press Mini shunt with mitomycin C induces less
      post-operative inflammation than trabeculectomy with mitomycin c.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to quantify the degree of post-operative inflammation in eyes
      which have undergone either trabeculectomy filtering surgery or Ex-Press mini shunt
      insertion. Early intraocular pressure control and postoperative complications will also be
      noted.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient population limited
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous humor flare</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueous humor cell</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with mitomycin c</intervention_name>
    <description>mitomycin c 0.2 mg/cc for 2 minutes</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ex-Press mini shunt with mitomycin c</intervention_name>
    <description>mitomycin c 0.2 mg/cc for 2 minutes</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must:

          1. Be willing and able to provide written Informed Consent.

          2. Be able and willing to follow instructions on the use of post- operative medication
             and likely to complete the entire course of the study.

          3. Be male or female of any race at least 18 years of age.

          4. Have medically uncontrolled glaucoma for which they have elected to undergo surgery.

          5. Diagnosed with primary open angle glaucoma, pigmentary or pseudoexfoliation glaucoma.

        Exclusion Criteria:

        No subject may:

          1. Have any contraindication to intraocular surgery.

          2. Diagnosed with: primary angle closure glaucoma, normal tension glaucoma, secondary
             glaucoma, neovascular glaucoma.

          3. Have any active ocular disease other than glaucoma that would interfere with study
             parameters (such as: uveitis, ocular infection, or severe dry eye). Subjects with mild
             chronic blepharitis, age-related macular degeneration and background diabetic
             retinopathy may be enrolled at the discretion of the investigator.

          4. Have laser ALT or SLT within the past 3 months or cataract surgery within the last six
             months.

          5. Require use of ocular NSAID or systemic steroids.

          6. Have known allergy or sensitivity to mitomycin C

          7. Have corneal abnormalities that would interfere with the ability to obtain an adequate
             laser flare measurement.

          8. Be concurrently enrolled in an investigational drug or device study or participation
             within the last 30 days in any investigational drug or device study.

          9. Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not
             using a reliable form of contraception (a woman is considered of childbearing
             potential unless she is postmenopausal, has had a uterus and/or both ovaries removed,
             or has had a bilateral tubal ligation).

         10. Have a situation or condition that in the investigator's opinion may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis B Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IU Eye at Carmel</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hille K, Hans J, Manderscheid T, Spang S, Ruprecht KW. [Laser flare in combined cataract and glaucoma surgery]. Ophthalmologe. 2001 Jan;98(1):47-53. German.</citation>
    <PMID>11220271</PMID>
  </reference>
  <reference>
    <citation>Maris PJ Jr, Ishida K, Netland PA. Comparison of trabeculectomy with Ex-PRESS miniature glaucoma device implanted under scleral flap. J Glaucoma. 2007 Jan;16(1):14-9.</citation>
    <PMID>17224744</PMID>
  </reference>
  <reference>
    <citation>Shah SM, Spalton DJ, Allen RJ, Smith SE. A comparison of the laser flare cell meter and fluorophotometry in assessment of the blood-aqueous barrier. Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3124-30.</citation>
    <PMID>8407220</PMID>
  </reference>
  <reference>
    <citation>Dahan E, Carmichael TR. Implantation of a miniature glaucoma device under a scleral flap. J Glaucoma. 2005 Apr;14(2):98-102.</citation>
    <PMID>15741808</PMID>
  </reference>
  <reference>
    <citation>Shields, MB Textbook of Glaucoma. Fourth Edition; Williams &amp; Wilkins, Baltimore, 1998.</citation>
  </reference>
  <reference>
    <citation>Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR Retina-Vitreous-Macula. W.B. Saunders Company, Philadelphia, 1999.</citation>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Louis B. Cantor, M.D.</name_title>
    <organization>Indiana University</organization>
  </responsible_party>
  <keyword>Inflammatory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

